MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Allogene Therapeutics Inc

Fechado

SetorSaúde

1.25 1.63

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.24

Máximo

1.31

Indicadores-chave

By Trading Economics

Rendimento

206K

-60M

Margem de lucro

272,450

Funcionários

226

EBITDA

-302K

-56M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+593.6% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

26M

282M

Abertura anterior

-0.38

Fecho anterior

1.25

Sentimento de Notícias

By Acuity

50%

50%

154 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Allogene Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de jul. de 2025, 21:01 UTC

Ganhos

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

18 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Basic Materials Roundup: Market Talk

18 de jul. de 2025, 20:46 UTC

Ganhos

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 de jul. de 2025, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 de jul. de 2025, 20:36 UTC

Ganhos

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 de jul. de 2025, 20:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 de jul. de 2025, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

18 de jul. de 2025, 20:02 UTC

Conversa de Mercado

Gold Higher to Close Out Week -- Market Talk

18 de jul. de 2025, 19:14 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 de jul. de 2025, 19:06 UTC

Conversa de Mercado

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 de jul. de 2025, 18:24 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 de jul. de 2025, 18:19 UTC

Ganhos

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 de jul. de 2025, 18:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 de jul. de 2025, 18:11 UTC

Ganhos

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 de jul. de 2025, 17:35 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 de jul. de 2025, 16:29 UTC

Conversa de Mercado

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 de jul. de 2025, 16:28 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 de jul. de 2025, 16:22 UTC

Ganhos

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

18 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Basic Materials Roundup: Market Talk

18 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

18 de jul. de 2025, 16:04 UTC

Ganhos

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 de jul. de 2025, 15:58 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

18 de jul. de 2025, 15:58 UTC

Conversa de Mercado

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 de jul. de 2025, 15:47 UTC

Conversa de Mercado
Ganhos

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparação entre Pares

Variação de preço

Allogene Therapeutics Inc Previsão

Preço-alvo

By TipRanks

593.6% parte superior

Previsão para 12 meses

Média 8.67 USD  593.6%

Máximo 14 USD

Mínimo 4 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Allogene Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

11

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.18 / 1.69Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

154 / 376 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.